Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Seeking Alpha
Brian Schoelkopf - Head of Investor Relations Todd Watanabe - President, CEO & Director L. Edwards - Executive VP & Chief Commercial Officer Patrick Burnett - Executive VP & Chief Medical Officer Latha Vairavan - Chief Financial Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Judah Frommer - Morgan Stanley, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Jin Law - Goldman Sachs Group, Inc., Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc. Fourth Quarter Fiscal Year 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would like now to turn the conference over to Brian Schoelkopf, Head of Investor Relations. Please
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone [Yahoo! Finance]Yahoo! Finance
- Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth [Yahoo! Finance]Yahoo! Finance
- Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of GrowthGlobeNewswire
- Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen [Yahoo! Finance]Yahoo! Finance
- Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis [Yahoo! Finance]Yahoo! Finance
ARQT
Earnings
- 2/25/26 - Beat
ARQT
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/3/26 - Form 4
- ARQT's page on the SEC website